Company Veloxis Pharmaceuticals A/S

VELO

DK0060048148

Pharmaceuticals

Delayed Nasdaq Copenhagen Other stock markets			5-day change	1st Jan Change
- ^DKK	-.--%		-.--%	-0.50%

24-05-30	Veloxis Pharmaceuticals A/S Selects to Present At the 2024 American Transplant Congress in Philadelphia	CI
22-06-28	Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard(R) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)	CI

Business description: Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals A/S is a Denmark-based commercial-stage specialty pharmaceutical Company. The Companyâ€™s product Envarsus XR (tacrolimus extended-release tablets) is a prescription medicine used with other medicines to help prevent organ rejection in people who have had a kidney transplant. It is based upon the Companyâ€™s patented delivery technology, MeltDose, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The Company operates in the United States through its subsidiary, Veloxis Pharmaceuticals Inc.

Executive Committee: Veloxis Pharmaceuticals A/S

Manager	Title	Age	Since
Daisuke Matsuo CEO	Chief Executive Officer	-	-
Ulf Meier-Kriesche CTO	Chief Tech/Sci/R&D Officer	-	2017-09-12
Stacy Wheeler COO	Chief Operating Officer	-	2016-02-29
Noel Barnard LAW	General Counsel	-	2016-02-29
Rita L. Mannella HRO	Human Resources Officer	-	2016-12-31

See VELOXIS PHARMACEUTICALS A/S governance

Company details: Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals A/S

Gdanskgade 18

2150, Copenhagen

https://www.veloxis.com/

address Veloxis Pharmaceuticals A/S(VELO)

Specialty & Advanced Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
VELOXIS PHARMACEUTICALS A/S	-.--%	-.--%	-	-	1.64B
MERCK KGAA	+0.63%	+2.03%	-6.06%	-30.66%	65.31B
HALOZYME THERAPEUTICS, INC.	-6.98%	-5.79%	+29.38%	+50.85%	9.46B
KYOWA KIRIN CO., LTD.	+1.86%	+1.94%	+29.17%	-9.78%	8.87B
SK BIOPHARMACEUTICALS CO., LTD.	-3.70%	-2.15%	-14.55%	+64.71%	5.92B
YUHAN CORPORATION	-0.55%	+0.55%	-12.68%	+121.83%	5.59B
INDIVIOR PHARMACEUTICALS, INC.	+2.00%	+3.29%	+225.02%	+85.26%	4.34B
MEZZION PHARMA CO.,LTD.	-2.42%	-4.22%	+418.93%	+931.23%	3.05B
SUPERNUS PHARMACEUTICALS, INC.	-1.18%	+0.24%	+29.47%	+32.57%	2.96B
BETTA PHARMACEUTICALS CO., LTD.	-2.59%	-4.06%	-9.15%	-22.27%	2.79B
Average	-1.27%	+0.04%	+76.61%	+135.97%	10.99B
Weighted average by Cap.	-0.38%	+0.61%	+21.25%	+24.97%